| Prev Close: | 104.53 |
|---|---|
| Open: | N/A |
| Bid: | 103.16 x 100 |
| Ask: | 103.50 x 200 |
| 1y Target Est: | 112.73 |
| Beta: | 0.54 |
| Next Earnings Date: | 22-Jul-13 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 67.61 - 114.95 |
| Volume: | 500 |
| Avg Vol (3m): | 4,249,610 |
| Market Cap: | 78.39B |
| P/E (ttm): | 17.69 |
| EPS (ttm): | 5.91 |
| Div & Yield: | 1.88 (1.80%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Thu, 06:08 SGT)
- Amag slumps on Ferahame recall in SwitzerlandAP(Thu, 02:18 SGT)
- Midday Glance: Biotechnology companiesAP(Thu, 01:17 SGT)
- Early Glance: Biotechnology companiesAP(Wed, 22 May)
- On the Call: Merck R&D director Roger PerlmutterAP(Thu, 2 May)
- Earnings Preview: Merck to key on coming new drugsAP(Tue, 30 Apr)
- Weak earnings prospects weigh on stocksAP(Thu, 25 Apr)
- P&G, AT&T drop after earnings, holding back DowAP(Thu, 25 Apr)
- Sales disappoint, but tax gain lifts Amgen profitAP(Wed, 24 Apr)
- Summary Box: Amgen profit rises on lower taxesAP(Wed, 24 Apr)
- Amgen Provides Long-Term UpdateZacks(Thu, 14 Feb)
- UCB, Amgen Discontinue StudyZacks(Wed, 13 Feb)
- The Zacks Analyst Blog Highlights: Kohl's, Actavis, Amgen, Mylan and Pernix Therapeutic HoldingsZacks(Fri, 1 Feb)
- Actavis Provides 2013 GuidanceZacks(Fri, 1 Feb)
- The Zacks Analyst Blog Highlights: Amgen, Celgene, Gilead Sciences, Vertex Pharmaceuticals and Nasdaq Biotechnology Index ETFZacks(Mon, 28 Jan)
Press Releases
- Amgen Announces Voting Results of Annual Meeting of StockholdersPR Newswire(Thu, 05:46 SGT)
- Amgen To Present At The UBS Global Life Sciences ConferencePR Newswire(Fri, 17 May)
- New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal CancerPR Newswire(Thu, 16 May)